Tuvirumab
Based on 1 Customer Validation
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research.
For research use only. We do not sell to patients.
- Purity : ≥99%
- CAS No.: 138660-97-6
- Molecular Weight:144.04 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 lambda
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
HBV
In Vivo
Tuvirumab (5 mg/kg; iv) has a half-life of 16.7 days in the chimpanzee[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 138660-97-6
-
Appearance Liquid
-
Molecular Weight 144.04 kDa
-
Color Colorless to off-white
-
SMILES
[Tuvirumab]
-
Synonyms
anti-hepatitis B; OST 577; SDZ-OST 577
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. N Ogata, et al. Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3014-8. [Content Brief]
[2]. R A Heijtink, et al. Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes. J Med Virol. 2001 Aug;64(4):427-34. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)